Side effects and good effects from new chemotherapeutic agents: Case 1. Gefitinib-induced interstital fibrosis

Journal of Clinical Oncology

Volumn 23, Issue 10, 2005, Pages 2423-2424

  Nagaria, Neil C ^a   Cogswell, Janet ^a   Choe, Jin K ^a   Kasimis, Basil ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CARBOPLATIN; DOCETAXEL; FLAVOPIRIDOL; GEFITINIB; PACLITAXEL; STEROID; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ANAMNESIS; AREA UNDER THE CURVE; ARTICLE; BRONCHOSCOPY; CANCER GROWTH; CANCER SIZE; CANDIDA ALBICANS; CASE REPORT; CLINICAL TRIAL; COMMON COLD SYMPTOM; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DYSPNEA; FATIGUE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG INFECTION; LUNG NON SMALL CELL CANCER; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; NEBULIZER; OXYGEN SUPPLY; PHYSICAL DISABILITY; PRIORITY JOURNAL; RESPIRATORY TRACT INTUBATION; THORAX RADIOGRAPHY; TRACHEOBRONCHIAL TOILET; TREATMENT FAILURE; CHEMICALLY INDUCED DISORDER; COUGHING; FATALITY; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG TUMOR; MIDDLE AGED;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COUGH; DYSPNEA; FATAL OUTCOME; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PULMONARY FIBROSIS; QUINAZOLINES;

EID: 17144386959     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.055     Document Type: Article

References (12)

1. Inoue A, Saijo Y, Maemondo M, et al: Severe acute interstitial pneumonia and Gefitinib. Lancet 361:137-139, 2003
2. Manufacturers' Prescribing Information in, Physicians' Desk Reference (ed 58). Montvale, NJ, Thomson PDR, 2004
3. Baughman RP, Lower EE, Miller MA, et al: Overexpression of transforming growth factor-alpha and epidermal growth factor receptor in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 16:57-61, 1999
4. Madtes DK, Busby HK, Strandjord TP, et al: Expression of Transforming Growth Factor alpha and epidermal growth factor receptor is increased following bleomycin induced lung injury in rats. Am J Respir Cell Mol Biol 11:540-551, 1994
5. Suzuki H, Aoshiba K, Yokohori N, et al: Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Clin Cancer Res, 63:5054-5059, 2003
6. Thrall RS, Scalise PJ: Bleomycin, in Phan SH, Thrall RS (eds): Pulmonary Fibrosis, New York, NY, Marcel Dekker Inc, 1995, pp 231-292
7. Selmen M, King TE Jr, Pardo A: Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134:134-151, 2001
8. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD 1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000
9. Kuwano K, Hagimoto N, Kawaski M, et al: Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Investig 104:13-19, 1999
10. Yasui S, Nagai A, Oohira A, et al: Effects of anti-mouse EGF antiserum on the prenatal lung development in fetal mice. Pediatr Pulmonol 15:251-256, 1993
11. Cohen MH, Williams GA, Sridhara R, et al: FDA Approval Summary: Gefitinib (ZD 1839) (Iressa) Tablets. Oncologist 8:303-306, 2003
12. Camus P, Fanton A, Bonniaud P, et al: Interstitial lung disease induced by drugs and radiation. Respiration 71:301-326, 2004